Sheller Urges Justices To OK Standing In FDA Risperdal Row

Law360, New York (March 17, 2017, 7:25 PM EDT) -- Sheller PC has asked the U.S. Supreme Court to declare it has standing to sue the FDA, arguing it was injured when the agency denied a citizen petition aimed at forcing a Johnson & Johnson unit to publicize documents about its antipsychotic drug Risperdal, in a related suit over side effects in adolescent boys.

The Third Circuit had upheld the dismissal of the suit, concluding any economic damage came from the drugmaker, Janssen Pharmaceuticals, not the U.S. Food and Drug Administration. But Sheller said Janssen’s argument was...
To view the full article, register now.